260526 Tracing HIV-1 CRF07_BC Epidemic Among Injcting Drug Users (IDUs) in Central Taiwan

Tuesday, October 30, 2012 : 9:15 AM - 9:30 AM

Yu-Ching Lan, PhD , Department of Health Risk Management, China Medical University, Taichung, Taiwan
Yi-Chen Yang , Department of health risk management, China Medical University, Taichung, Taiwan
Introduction and Objectives: According to statistics from the Taiwan Centers for Disease Control, at the end of 2011 just near one-third (29.9%) of HIV-1-positive Taiwanese were injecting drug users (IDUs), representing the highest at-risk group. In the previous study, we noted higher levels of CRF07_BC circulation among IDUs. This study investigated CRF07_BC transmission origin among IDUs population. Methods: Blood samples and clinical data were collected from HIV-1-positive IDUs patients at a medical center in central Taiwan between 2007 and 2009. To trace origin entry times for CRF07_BC among IDUs, we performed estimations of evolutionary rates and dates of the most recent common ancestor (tMRCA). Results: According to Bayesian tree, the CRF07_BC viral strain went through a period of incubation in southern Taiwan prior to transmission to northern Taiwan and an immediate return to central Taiwan via a founder strain. The evolution rate of CRF07_BC is 0.7810-2 (0.5310-2-1.0510-2, 95% Highest Posterior Density (HPD)).The tMRCA of CRF07_BC were dated to 2002.3 (2000.2-2003.7, 95% HPD), and the demographic history of the population shown in the skyline plot indicated CRF07_BC in central Taiwan was increasing. Conclusion: The CRF07_BC strain transmission origin among IDUs was trace back 2002. Furthermore, the CRF07_BC strain was increasing in central Taiwan.

Learning Areas:
Public health biology

Learning Objectives:
Identify CRF07_BC transmission origin among IDUs population.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the PI of this research project.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4043.0: HIV and Injection Drug Use